The National Institute of Allergy and Infectious Diseases estimates that up to 45 percent of deaths in the developed world involve chronic fibrotic processes. Under a patent license from the Burnham Institute for Medical Research (Burnham) in which Burnham researcher Dr. Erkki Ruoslahti is a named inventor, Genzyme Corporation is conducting clinical trials on GC-1008, an anti-fibrotic drug.

Leave a Reply

Your email address will not be published. Required fields are marked *